--- title: 'Industry Daily Summary: What Happened on October 13, 2026' headline: Roche strikes $1 billion deal with Rona on RNAi obesity treatment description: Pfizer and Enodia also agreed to discover drugs that target proteins as cells make them, in a deal that could exceed $500 million. url: https://thebench.bio/news/industry/2026-10-13 topic: industry date: '2026-10-13' covers: - '2026-10-13' date_published: '2026-10-13T12:03:29Z' date_modified: '2026-10-13T12:03:29Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on October 13, 2026 **Roche strikes $1 billion deal with Rona on RNAi obesity treatment** Pfizer and Enodia also agreed to discover drugs that target proteins as cells make them, in a deal that could exceed $500 million. ## Today in brief Roche’s $1 billion agreement with Rona centers on RNA interference as a possible obesity treatment approach. [1] A Pfizer-Enodia collaboration will search for small molecules that act on proteins during their production, with potential payments topping $500 million. [2] ## Roche makes a $1 billion RNAi obesity deal with Rona Roche agreed to a $1 billion deal with Rona focused on RNA interference, or RNAi, for obesity treatment. [1] Roche is among the companies exploring RNAi as an approach to obesity treatment. [1] ## Pfizer and Enodia will target proteins during synthesis Pfizer and Enodia Therapeutics will discover small molecules that target proteins as cells make them. [2] Enodia will lead discovery work on multiple undisclosed targets. Pfizer will handle later clinical development, manufacturing, regulatory work and commercialization. [2] The agreement includes an upfront payment and could exceed $500 million in total value, including milestones and royalties. [2] Enodia is developing machine-learning-designed molecules to modulate Sec61, a cellular channel involved in protein production. The company says its platform could support work in inflammation, immunology and cancer. [2] ## The day in numbers - **$1 billion**: Value of Roche’s deal with Rona focused on RNAi-based obesity treatment. [1] - **More than $500 million**: Potential total value of Pfizer and Enodia’s collaboration, including upfront payment, milestones and royalties. [2] ## Also published - [An All-Encompassing Update: Thoughts On 16 Companies](), Matt Gamber - [Changing Faces: Digital and supplier hires, September 2026](), pharmaphorum - [The biotech bi-weekly: identifying disease-relevant splice variants, launching a next-generation sequencing panel and integrating AI into disease and therapeutic research](), BioTechniques - [High-quality FFPE tissue blocks for biomarker discovery](), BioTechniques - [Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts](), Pharmaceutical Executive - [How a changing environment is reshaping mental health](), EMBL ## Sources 1. [Roche bets on the RNAi approach for obesity through $1bn Rona deal  ](), Pharmaceutical Technology, 2026-10-13 2. [Enodia lands $500M Pfizer deal to target proteins at the point of synthesis](), European Biotechnology, 2026-10-13 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: